Trump's Drug Tariffs May Raise Costs for Millions of Patients

WHO:

Fast Company - Trump stated that facilities for drug manufacturing are being built across the U.S. “at a level never seen before.”

Fast Company - Richard Saynor is the CEO of Sandoz, which makes more than 400 generic drugs.

CNBC - President Trump proposed tariffs on imported generic medicines.

CNBC - John Murphy III is the president and CEO of the Association for Accessible Medicines.

CNBC - Salil Kallianpur is an independent pharmaceutical consultant.

CNBC - Namit Joshi is the chairman of India's Pharmaceuticals Export Promotion Council (Pharmexcil).

WHAT:

Fast Company - Trump announced that a 100% tariff on imported generic medications would begin in August 2028, rising to 200% in August 2029.

Fast Company - Shares of various European and Asian companies that manufacture generic drugs fell as much as 4.3% following Trump's announcement.

CNBC - Trump proposed tariffs on imported generic medicines that would initially face no tariffs for two years, then rise to 100% for one year, and finally to 200%.

CNBC - The global generic drug industry is currently worth nearly $500 billion.

CNBC - Generic medicines account for about 90% of prescriptions in the U.S.

CNBC - Many manufacturers have limited room to absorb tariffs as high as 100% or 200%.

CNBC - Building a domestic generic drug manufacturing ecosystem takes a minimum of four to five years.

WHERE:

CNBC - Many generic medicines sold in the U.S. are manufactured in India, while China supplies many of the active pharmaceutical ingredients.

WHEN:

Fast Company - Trump announced that a 100% tariff on imported generic medications would begin in August 2028, rising to 200% in August 2029.

CNBC - The tariffs are set to take effect after a two-year period.

WHY:

Fast Company - Nathan Gray, a senior research fellow at the Institute for International Trade at Adelaide University, stated that tariffs on generic drugs could end up having the opposite effect than Trump intends, potentially increasing costs for consumers.

Fast Company - Trump stated that the goal of the tariffs is to reshore production “to protect the people of the United States.”

CNBC - The administration argues that tariffs will help bring pharmaceutical manufacturing back to the U.S. and strengthen domestic supply chains.

Newsweek - Policy expert Rena Conti stated that the policy could cause generic drug shortages or aggravate existing shortages.

HOW:

Fast Company - The Indian Pharmaceutical Alliance indicated that tariffs alone would not lead to sustainable onshoring of generic-medicine production to the U.S.

CNBC - Manufacturers facing higher costs would have limited options: absorb the tariffs, pass them on to customers, invest in shifting production to the U.S., or stop selling products that become uneconomic.

CNBC - The economics are particularly challenging for commodity generic manufacturers that export to the U.S.

(UPDATED July 22, 2026 21:20 UTC)

Trump announced that facilities for drug manufacturing are being built across the U.S. “at a level never seen before,” and he revealed plans for a 100% tariff on imported generic medications starting in August 2028, which will rise to 200% in August 2029. Following this announcement, shares of various European and Asian companies that manufacture generic drugs fell as much as 4.3%. Experts like Nathan Gray from the Institute for International Trade have warned that these tariffs could inadvertently increase costs for consumers, while the Indian Pharmaceutical Alliance noted that tariffs alone may not lead to sustainable onshoring of generic-medicine production to the U.S.

(UPDATED July 22, 2026 20:24 UTC)

Trump has announced that a 100% tariff on imported generic medications will begin in August 2028, increasing to 200% in August 2029. He stated that the goal of these tariffs is to reshore production to protect the people of the United States. However, the Indian Pharmaceutical Alliance has indicated that tariffs alone will not lead to sustainable onshoring of generic medicine production to the U.S.

(UPDATED July 22, 2026 16:26 UTC)

President Trump has proposed a series of tariffs on imported generic medicines, which would start with no tariffs for two years, then increase to 100% for one year, and ultimately reach 200%. The global generic drug industry, valued at nearly $500 billion, plays a crucial role in the U.S. market, where generic medicines account for about 90% of prescriptions, but many manufacturers may struggle to absorb such high tariffs. The administration believes these tariffs will encourage domestic pharmaceutical manufacturing, although experts warn that they could lead to shortages of generic drugs already in limited supply.